Physician profile
Mini K Das
NPI 1154329449
$1,207.97
in general payments reported to CMS, 2019-2025
19 companies · $252 in 2025
The $252 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $120 · 2020: $117 · 2021: $204 · 2022: $172 · 2023: $100 · 2024: $244 · 2025: $252.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $596.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $595.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $257.90 | 2019-2025 | Eliquis, Camzyos |
| Janssen Pharmaceuticals, INC | $163.79 | 2020-2022 | |
| Pfizer INC. | $154.77 | 2021-2024 | |
| Medtronic, INC. | $146.22 | 2025 | Simulus |
| Irhythm Technologies, INC. | $72.57 | 2022 | |
| Novartis Pharmaceuticals Corporation | $68.98 | 2019-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $55.24 | 2019-2020 | |
| Novo Nordisk INC | $52.26 | 2023-2024 | Ozempic, Rybelsus |
| Lantheus Medical Imaging, INC. | $50.12 | 2020-2022 | |
| Regeneron Healthcare Solutions, INC. | $24.29 | 2019 | |
| Abbott Laboratories | $24.19 | 2022 | |
| Vital Connect, INC | $22.67 | 2024 | Vitalpatch Rtm |
| Kiniksa Pharmaceuticals, Ltd. | $22.41 | 2023 | Arcalyst |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.76 | 2025 | Jardiance |
| Kiniksa Pharmaceuticals International, Plc | $16.48 | 2024 | Arcalyst |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $15.83 | 2022 | |
| Philips North America LLC | $15.59 | 2025 | Mcot |
| Sanofi-Aventis U.S. LLC | $14.39 | 2024 | |
| Kowa Pharmaceuticals America, INC. | $13.51 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mini Das listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.